Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms

Maira da Costa Cacemiro1 · Juçara Gastaldi Cominal1 · Luiz Miguel Pereira1 · Maria Gabriela Berzoti-Coelho1 · Giovana Michelassi Berbel1 · Luciana Baroni1 · Tathiane Malta1 · Raquel Tognon2 · Natalia de Souza Nunes1 · Elizabeth Xisto Souto4 · Lorena Lobo de Figueiredo-Pontes3 · Ana Patrícia Yatsuda1 · Fabíola Attié de Castro1

Received: 23 November 2021 / Accepted: 22 February 2022 / Published online: 23 May 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

Myeloproliferative neoplasms (MPN) are hematological disorders characterized by increased proliferation of precursor and mature myeloid cells. MPN patients may present driver mutations in \( JAK2 \), \( MPL \), and \( CALR \) genes, which are essential to describe the molecular mechanisms of MPN pathogenesis. Despite all the new knowledge on MPN pathogenesis, many questions remain to be answered to develop effective therapies to cure MPN or impair its progression to acute myeloid leukemia. The present study examined the expression levels of the Hippo signaling pathway members in patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), as well as the role that they play in disease pathogenesis. The Hippo pathway is a tumor suppressor pathway that participates in the regulation of cell proliferation, differentiation, and death. Our main finding was that the expression of tumor suppressor genes from Hippo pathway were downregulated and seemed to be associated with cell resistance to apoptosis and increased proliferation rate. Therefore, the decreased expression of Hippo pathway-related genes may contribute to the malignant phenotype, apoptosis resistance, and cell proliferation in MPN pathogenesis.

Keywords Myeloproliferative neoplasms · Hippo signaling pathway · Apoptosis · Cell proliferation · LATS2
Introduction

Polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET) are Philadelphia-negative myeloproliferative neoplasms (MPN) characterized by increased proliferation of mature myeloid cells from one or more hematopoietic series: granulocytic, erythroid, and megakaryocytic. The MPN neoplastic cells are resistant to death and present exacerbated proliferation rate [1, 2].

Deregulated expression of pro- and antiapoptotic genes is an important mechanism of myeloid cell death and accumulation in MPN. Apoptosis, one of the best-characterized mechanisms of programmed cell death, clearly plays a role in hematopoiesis control. However, the exact pathways that are affected in BCR-ABL1-negative MPN have not yet been fully clarified [3]. Expression of the anti-apoptotic genes A1, BCL2, BCL-XL, and BCL-W is upregulated while expression of the pro-apoptotic genes BID and BIM is downregulated in leukocytes from ET patients [4]. The JAK2V617F allele burden correlates with BAX, BIK, BAD A1, BAX, BIK, and PRV1 gene expression [4].

Abnormal cytokine production by both malignant and nonmalignant cells is associated with increased JAK2-STAT3 activation and accounts for apoptosis inhibition and enhanced myeloproliferation, which create an environment that favors MPN clone maintenance and expansion [3].

The landmark of the MPN pathophysiological findings is description of the JAK2V617F mutation, present in about 95% of PV patients and in approximately 50% of PMF and ET patients [5, 6]. The JAK2V617F mutation is caused by the replacement of the amino acid valine by phenylalanine at codon 617 (JAK2V617F), with consequent constitutive activation of the JAK-STAT signaling pathway that stimulates proliferation of myeloid hematopoietic precursors [7]. The JAK2V617F mutation leads to accumulation of irreparable DNA damage that triggers the apoptotic cascade, with high BNIP-3 positivity, eliciting megakaryocyte apoptosis [3]. This process is counteracted by phosphorylated STAT5 (pSTAT5). Phosphorylated STAT3 (pSTAT3) induces BCL-XL expression, which confers resistance to apoptosis to myeloid cells [8].

The MPL mutation results from the replacement of tryptophan at codon 515 by arginine, leucine, lysine, or alanine [9]. This mutation occurs in approximately 10% of JAK2V617F-negative PMF and ET patients [9]. Tryptophan at position 515 prevents MPL dimerization in the absence of cytokines; however, its replacement by other amino acids enables dimerization and leads to the constitutive activation of the receptor and the JAK-STAT pathway, with consequent exacerbated proliferation of myeloid cells [10]. The antiapoptotic effect remains after cytokine withdrawal in MPLW515K/L-expressing cell lines characterized by high levels of BCL-XL expression [11].

CALR indel mutations are located in the exon 9 of the gene and result in a C-terminus that loses the endoplasmic reticulum retention motif. The mutated CALR constitutively activates the MPL receptor, even in the absence of thrombopoietin, and induces cell transformation, probably by stimulating MPL-JAK2 signaling [12]. Mutation in the CALR gene induces activation of the JAK2/STAT/phosphatidylinositol-3'-kinase and mitogen-activated protein pathways via MPL, leading to exacerbated proliferation of myeloid cells [13]. CALR mutants have weaker pro-apoptotic signals downstream the unfolded protein response, which leads to accumulation of misfolded proteins in endoplasmic reticulum and resistance to apoptosis induced by the unfolded protein response [14].

Despite the latest knowledge about the molecular and cellular mechanisms of MPN pathogenesis, the only curative treatment for this disease is bone marrow transplantation, but most patients are ineligible for the procedure. In this sense, our research team have investigated how the Hippo signaling pathway participates in MPN physiopathology.

The Hippo signaling pathway is a tumor suppressor pathway that plays a role in regulation of cell proliferation, differentiation and death [15]. The Hippo signaling cascade is composed of MST1/MST2, SAV1, LATS1/LATS2, MOB1A/MOB1B, YAP, and TAZ proteins. Activation of the classical pathway begins with MST1/MST2 and its adapter protein SAV1 phosphorylation by different regulatory signals. MST1/2 proteins phosphorylate and activate LATS1 and LATS2 in a process that requires interaction with the small proteins MOB1A, MOB1B, MOB2A, and MOB2B. Activated LATS1/2 proteins may phosphorylate different serine/threonine residues from YAP and TAZ transcriptional factors. When YAP is phosphorylated at serine 127 or 381 and TAZ is phosphorylated at serine 89 or 311, they bind to the 14.3.3 protein complex in the cytoplasm, which inhibits its transcriptional activity and promotes the retention and cytosolic degradation of YAP/TAZ [16, 17].

When the pathway is inactive, YAP/TAZ translocates to the cell nucleus and associates with transcription factors from the TEAD1-4 (TEAD/TEF) family to trigger expression of target genes such as connective tissue growth factor (CTGF), cysteine-rich angiogenic inducer 61 (CYR61), and fibroblast growth factor 1 (FGF1), which mediate cell proliferation and apoptosis impairment [18].

Springer
 Subjects and methods

Ethical approval

The institutional review board from the School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP-USP) and Ribeirão Preto Medical School Hospital (HC-FMRP-USP) at University of São Paulo approved the study protocol (CAAE 30901714.3.3001.5440). All patients and healthy subjects signed an informed written consent form that complied with the Brazilian National Health Council guidelines (law 466/2012).

Subjects

This study enrolled ET, PMF, and PV patients followed at HC-FMRP-USP and at Euryclides de Jesus Zerbini Transplant Hospital, São Paulo-SP, Brazil. For peripheral blood, ET patients' group was composed of 35 individuals (9 males, 26 females) with mean age of 59 years: 15 patients harbored JAK2V617F mutation and 9 patients harbored CALR mutation. The PMF patients' group was composed of 22 individuals (15 males, 7 females) with mean age of 62 years: 12 patients harbored the JAK2V617F mutation and 5 harbored the CALR mutation. The PV patients' group was composed of 31 individuals (14 males, 17 females) with mean age of 65 years: 30 harbored the JAK2V617F mutation and one was negative for all the three mutations. The control group comprised 60 healthy individuals (21 males, 39 females) with mean age of 56 years, who lived in Ribeirão Preto, State of São Paulo, Brazil (Table S1).

Blood samples

The patients’ and healthy subjects’ peripheral blood was collected using EDTA tubes (Vacutainer®; Becton, Dickinson, and Company). The patients’ blood samples were collected at the time of diagnosis, based on the WHO 2016 [19] criteria; therefore, none of them were under therapy at the time of blood collection. Exclusion criteria for controls were the presence of neoplasms, autoimmune diseases, viral infections, HIV, or diabetes.

Clinic-hematological data

The red blood cell count (RBC), white blood cell count (WBC), platelet number, hemoglobin concentration (Hb), and hematocrit percentage (Ht) were determined using the automatic equipment ABX Micros 60 (HORIBA ABX SAS). Data from hematological parameters are reported in Table S1. Clinical data as LDH, thrombotic events, blasts percentage, and spleen size were obtained from the medical record.

Isolation of CD34+ hematopoietic precursor cells

Five mL of bone marrow samples were collected from patients and healthy donors. The bone marrow mononuclear cells were isolated using the Ficoll-Hypaque (Sigma-Aldrich) method. After washing with 0.05% albumin (Sigma-Aldrich) in PBS-ACD buffer, the cells were suspended in the same buffer and centrifuged. Then, the cell pellets were sequentially treated with Fc-blocking antibody (MidiMACS®—Miltenyi Biotech) and the primary anti-CD34-hapten antibody (MidiMACS®—Miltenyi Biotech). The cells were incubated at 4 °C for 20 min in the dark, diluted with 30 mL of PBS-ACD-albumin buffer, and centrifuged at 240 × g, for 10 min, at 4 °C.

Next, the secondary anti-hapten antibody (MidimACS®—Miltenyi Biotech) conjugated with microbeads was added to the cell pellet, followed by incubation at 4 °C for 20 min in the dark. The suspension was diluted with 20 mL of PBS-ACD-albumin buffer and centrifuged at 240 × g, for 10 min, at 4 °C. The cell pellet was suspended in 10 mL of PBS-ACD-albumin buffer, and applied on the magnetic column. The column was washed twice with the same buffer, far from the magnetic support, to release the CD34+ cells. The eluate was centrifuged at 240 × g, for 10 min, at 4 °C. The cell pellet was suspended in RPMI 1640 medium (Gibco), and the cells were counted in a Neubauer chamber. The purity of the CD34+ population was analyzed by flow cytometry; samples with purity above 85% were considered suitable for use. The concentration of bone marrow hematopoietic cells was adjusted to 2 × 10^5 in 500 µL of Trizol® (Invitrogen Life Technologies®) and the suspension was frozen for further RNA extraction.

Isolation of peripheral blood leukocytes from patients and control subjects

Isolation of peripheral blood leukocytes from patients and control subjects relied on the principle of density difference among leukocytes, red blood cells, and platelets using
Voluven (Fresenius) [20]. The protocol consists of adding four parts of whole blood to one part of Voluven, followed by 90 min of incubation. The supernatant was collected and centrifuged at 400 × g for 15 min. Cells were suspended in phosphate-buffer saline (PBS; pH = 7.4), diluted in 0.4% trypan blue (Sigma-Aldrich), and counted in Neubauer chamber. Leukocyte suspension at 1 × 10^7 cells/mL was frozen in Trizol® (Invitrogen Life Technologies®) for further RNA extraction.

**Cell culture**

The human cell line HEL.92.1.7 (erythroblastic cell line—HEL.92.1.7—ATCC® TIB-180™) harbors the JAK2V617F mutation. HEL.92.1.7 cells were cultured in RPMI 1640 medium (Invitrogen Life Technologies®) supplemented with 10% fetal bovine serum, 1% glutamine, 1% penicillin, and 1% streptomycin (Gibco®) under an atmosphere of 5% CO_2, at 37 °C. HEL.92.1.7—ATCC® TIB-180™ cells were cultured in RPMI 1640 medium (Invitrogen Life Technologies®) supplemented with 10% fetal bovine serum, 1% glutamine, 1% penicillin, and 1% streptomycin (Gibco®) under an atmosphere of 5% CO_2, at 37 °C.

**Cell treatment with JAK inhibitor I**

HEL.92.1.7 cells (5 × 10^6/mL) were treated with 10 µM of JAK Inhibitor I – an ATP-competitive inhibitor of JAK1, JAK2, JAK3, and TyK2 (Calbiochem, EMD Millipore Corp, Billerica, MA, USA) – for (i) 6, 12, and 24 h for Hippo pathway and apoptosis gene expression assays; (ii) 48 h for annexin-V assay; and (iii) 24, 48, and 72 h for cell proliferation assay. Next, part of the cell suspension was used in cell death and proliferation assays, and part was stored in Trizol® for RNA extraction and qPCR assays.

**Cell death quantification**

After JAK Inhibitor I treatment, 1 × 10^5 HEL.92.1.7 cells per tube were diluted with 500 µL of PBS and centrifuged at 240 × g for 10 min, at 4 °C. The supernatant was discarded, the cell pellets were suspended in 100 µL of annexin-binding buffer (250 µg/mL), and incubated for 20 min, in the dark, at 4 °C. The cells were washed three times with PBS and suspended in 200 µL of binding buffer containing 1 µL of propidium iodide. The percentage of apoptosis (annexin-V-FITC+ cells) was determined in a flow cytometer (FACS-Canto, BD), based on acquisition of 10,000 events to quantify cell proliferation. The results were expressed as fluorescence intensity and plotted as histograms. Cell proliferation was inversely proportional to CTV labeling.

**Transient expression of LATS2 gene**

The plasmid pClneoMyc-LATS2 (Addgene catalog number: #66,852) was used for LATS2 expression (Bao et al., 2011). Hel 92.1.7 cells were cultured in 75 cm^2 flasks (as described above), harvested, centrifuged (400 × g, 5 min, 4 °C), and washed with PBS. The cells were counted in Neubauer chamber and normalized to 1 × 10^7/mL. The cells were pelleted (1 × 10^7/plasmid) and suspended in 5 µg of pClneoMyc-LATS2 in RPMI. The cell suspensions were transferred to 4-mm sterile gap cuvettes and pulsed (250 V; 950 μF) in a BioRad GenePulser Xcell [21, 22]. As control, cells were transfected with pcDNA3.1 (ThermoFisher, catalog number: #V790-20) under the same conditions. After transfection, the cells were transferred to 75 cm^2 flasks and maintained in RPMI supplemented with 10% bovine fetal serum for 72 h, at 37 °C, and under 5% CO_2. The overexpression of LATS2 was confirmed by RT-PCR (Fig. S1). After 72 h of culture, the transfected cells were harvested and treated with 10 µM of JAK inhibitor I for (i) 48 h to analyze cell death rate; and (i) 24, 48, and 72 h to examine whether LATS2 overexpression affected cell proliferation.

**RNA extraction and cDNA synthesis**

The lysed cells in Trizol were treated with 10 µL glycogen (20 µg/µL) for 5 min, at room temperature. Then, 300 µL of cold chloroform was added to the mixture and the sample was shaken for 15 s. After centrifugation (12,000 × g, 15 min, 4 °C), the aqueous phase was transferred to a new tube and mixed with 500 µL of cold isopropanol. The mixture was stored at—20 °C overnight and centrifuged (12,000 × g, 15 min, 4 °C). The supernatant was discarded and the precipitate was washed with 70% cold ethanol and centrifuged (12,000 × g, 10 min, 4 °C). The supernatant was discarded and the pellet (RNA) was suspended in DNase- and RNase- free water. RNA was quantified using the NanoVue Spectrophotometer (GE Healthcare) at 260 nM.

Reverse transcription reactions were performed using 1 µg of RNA and the High Capacity cDNA reverse
transcription (Applied Biosystems) assay kit. Polymerization of the novel complementary DNA strands (cDNA) was performed in a thermocycler apparatus (Masterecycler, Eppendorf) at 25 °C, for 10 min, to promote primer annealing, followed by a 2-h step at 37 °C for the extension of the novel DNA strands.

Quantification of target genes by real-time PCR

Real-time PCR assays were performed on the StepOnePlus (Thermo Fisher) using the TaqMan gene expression assay kit (Applied Biosystems®). The Hippo pathway probes used are described in Table S3. As the TaqMan probe (Hs00371735_m1) did not detect the YAP1 gene, we used the Sybr green master mix kit (Thermo Fisher) and the primer pair sequence employed for RNA quantification described in Table S4. The Sybr green master mix kit (Thermo Fisher) was also used to analyze pro- and anti-apoptotic gene expression.

The oligonucleotide sequences employed in amplification of the target genes are described in Table S4. The gene expression results were reported as relative expression unit (REU = 10,000/2ΔCt) for patients or Fold Change for cell line. The ΔCt = CT of the target gene—geometric mean of the other reference genes CTs. REU = 10,000 / 2deltaCt.

Statistical analyses

The groups were compared using analysis of variance (ANOVA) followed by Tukey’s post-test for multiple comparisons. These models assume that their residuals have a normal distribution with a mean of 0 and a constant σ² variance. Transformation in the response variable was used when this assumption was not observed. All the graphs presented were plotted using the R software, version 4.0.4, while data analysis was performed using the SAS 9.4 software. For all comparisons, a significance level of 5% was adopted and correlation analyses were performed using the Pearson’s correlation test. Wild type (WT), MOCK, and LATS2 differences were compared using ANOVA, with the aid of the GraphPad Prism 8.0 software (Graph-Pad Software, San Diego, CA, USA). Statistical differences were considered significant when \( p < 0.05 \).

Results

Hippo pathway-related genes are less expressed in MPN leukocytes

The expression levels of Hippo pathway-related genes were compared among MPN categories and the control group. Compared with the control group: (i) \( MST1 \) \( (p < 0.04) \), \( MST2 \) \( (p < 0.01) \), \( LATS2 \) \( (p = 0.04) \), and \( YAP \) \( (p = 0.02) \) genes were less expressed in PV patients (Fig. 1); (ii) \( SAV1 \) \( (p < 0.01) \) and \( YAP \) \( (p = 0.04) \) genes were less expressed in ET patients (Fig. 1); and (iii) \( SAV1 \) \( (p < 0.01) \) and \( TAZ \) \( (p < 0.01) \) genes were less expressed in PMF patients (Fig. 1).

\( MST2 \) gene was less expressed in PV patients than in ET \( (p < 0.01) \) and PMF \( (p < 0.01) \) patients. In contrast, \( SAV1 \) gene was more expressed in PV patients than in ET \( (p < 0.01) \) and PMF \( (p < 0.01) \) patients. \( TAZ \) gene was less expressed in PV patients compared with ET \( (p < 0.01) \) and PMF \( (p < 0.01) \) patients. \( YAP1 \) gene was more expressed in PMF patients when compared with PV \( (p = 0.01) \) and ET \( (p = 0.04) \) patients (Fig. 1). The expression of other Hippo pathway-related genes did not differ among the analyzed groups. \( p > 0.05 \).

YAP/TAZ genes are deregulated in MPN CD34+ cells

\( TAZ \) expression levels were lower in PV patients than in control \( (p = 0.04) \). \( YAP1 \) RNA levels were higher in ET patients than in control \( (p < 0.01) \), PV \( (p < 0.01) \), and PMF \( (p < 0.01) \) groups (Fig. 2). The expression levels of other Hippo pathway-related genes did not differ among the analyzed groups. \( p > 0.05 \).

JAK2V617F and CALR mutation status influence Hippo pathway-related genes expression in peripheral leukocytes from ET and PMF patients

Compared with PMF JAK2V617F+ patients, \( MST1 \) \( (p = 0.02) \) gene was less expressed in JAK2V617F-negative patients and more expressed in CALR+ PMF patients \( (p = 0.04) \) (Fig. S3A). \( MOB1A \) was more expressed in CALR+ than in JAK2V617F+ PMF patients \( (p = 0.05) \); Fig. S3A). In contrast, \( MOB1B \) gene was more expressed in CALR+ PMF patients than in JAK2V617F+ \( (p < 0.01) \); Fig. S3A) and CALR− \( (p = 0.01) \); Fig. S3A) PMF patients. Compared with CALR+ ET patients, \( MOB1B \) \( (p = 0.02) \) and \( SAV1 \) \( (p < 0.01) \) were less expressed in CALR− ET patients \( (p = 0.02 \) and \( p < 0.01 \), respectively; Figure S3B) and double negative (JAK2V617F−/CALR−) ET patients \( (p = 0.01 \) and \( p < 0.01 \), respectively; Fig. S3B). There was no correlation between drive mutation status and the expression level of the other Hippo pathway genes analyzed (Fig. 2).

Hippo pathway and apoptosis-related genes expression are correlated with hematological and clinical data in MPN patients

We used heatmap of correlation to depict the correlations among Hippo pathway and apoptosis-related genes, and patients’ clinic-hematological data. The correlation profile differed among the MPN types studied. ET
patients presented negative correlations between BCL-X\textsubscript{L} expression and WBC count; thrombotic events and MST1, MOB1A, and YAP1 expression; LDH level and BAD expression (Fig. S4). PV patients presented negative correlations between platelet counts and LATS1, LATS2, MST1, and MST2 gene expression and positive correlations between BCL-X\textsubscript{L} and RBC count and between blasts percentage and MST1 and MST2 expression (Fig. S5). PMF presented negative correlations between platelets and MST1, MOB1A, BAD, BLC-2, and BCL-X\textsubscript{L} expression; and between WBC and MST1, MST2, MOB1A, MOB1B, SAV1, BAK, BLC-2, and BCL-X\textsubscript{L} expression (Fig. S6).

The apoptosis-related genes expression is deregulated in MPN patients' leukocytes

Compared with the control group, the pro-apoptotic BAD gene was less expressed in PV, ET, and PMF patients ($p < 0.01$; Fig. 3A), while the pro-apoptotic gene BAK was less expressed in PV ($p < 0.01$) and ET ($p < 0.01$) patients (Fig. 3B). The anti-apoptotic gene BCL-2 was more expressed in ET patients than in control group ($p < 0.01$), PV ($p = 0.01$), and PMF ($p = 0.02$) patients (Fig. 3C), while the anti-apoptotic gene BCL-X\textsubscript{L} was more expressed in PV ($p < 0.01$) and ET ($p < 0.01$) patients than in control group and PMF patients ($p < 0.01$) (Fig. 3D).
Fig. 2 Expression levels of the pro-apoptotic genes BAD (A) and BAK (B) and the anti-apoptotic genes BCL-2 (C) and BCL-XL (D) in leukocytes from patients with myeloproliferative neoplasms. Data from control subjects (CT) and patients with essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) are expressed as relative expression. Mann–Whitney statistical test.

Fig. 3 Expression of Hippo pathway-related genes in HEL.92.1.7 cells treated with JAK inhibitor I (JIII). LATS1, LATS2, MST1, MST2, MOB1A, MOB1B, and TAZ gene expression increased after 6 h of treatment. LATS1, MST1, MST2, SAV1, MOB1A, and TAZ gene expression increased after 12 h of treatment. The red line represents untreated cells. Data are expressed as Fold Change. Unpaired test.
JAK inhibitor I affects the expression of Hippo pathway- and apoptosis-related genes

HEL.92.1.7 cells treated with JAK inhibitor I exhibited increased expression of: (i) LATS1 ($p = 0.04$ and $p < 0.01$, respectively), MST2 ($p = 0.03$ and $p < 0.01$, respectively), and MOB1A ($p < 0.01$ for both) after 6 and 24 h of treatment; (ii) LATS2 after 6 and 12 h of treatment ($p < 0.01$ for both); (iii) MST1 ($p = 0.01$, $p < 0.01$, and $p < 0.01$, respectively) and TAZ ($p = 0.02$, $p < 0.01$, and $p = 0.02$, respectively) after 6, 12, and 24 h of treatment; (iv) SAV1 after 24 h of treatment ($p = 0.03$); (v) MOB1B genes after 6 h of treatment ($p < 0.01$) (Fig. 4).

After treatment with JAK inhibitor I, expression of the following apoptosis-related genes was upregulated: (i) BAD after 12 h of treatment ($p = 0.02$); (ii) BCL-2 after 6 and 24 h of treatment ($p < 0.01$ for both); and (iii) BCL-XL after 6 h of treatment ($p = 0.01$). In contrast, JAK inhibitor I downmodulated BAK and BCL-XL gene expression after 12 h ($p = 0.03$ and $p < 0.01$, respectively) and 24 h ($p = 0.04$ and $p < 0.01$, respectively) of treatment (Fig. 5).

LATS2 transient expression and JAK2 inhibitor alter HEL.92.1.7 cell death and proliferation rates

HEL.92.1.7-LATS2 cells were less resistant to JAK inhibitor I-induced cell death than HEL.92.1.7.-pcDNA3.1 (MOCK) cells ($p = 0.01$) and wild-type cells ($p < 0.01$) (Fig. 6). HEL.92.1.7-LATS2 cells were less resistant to cell death than wild-type cells and MOCK cells, since the transfection process itself caused death of part of the cells (Fig. 6).

Treatment with JAK2 inhibitor for 24 h decreased the cell proliferation rate of HEL.92.1.7-LATS2 cells when compared with MOCK-transfected cells (Fig. 6). LATS2-transfected cells treated or not with JAK2 inhibitor for 12 or 24 h had lower proliferation rate than wild-type cells.

Discussion

The Hippo signaling pathway has emerged as a complex signaling network related to molecular mechanisms involved in cancer development and progression [23, 24]. In mammals, Hippo pathway deregulation contributes to the
pathophysiology of various clinical disorders. The altered expression of Hippo pathway-related genes is associated with tumorigenesis of colorectal cancer [25], lung cancer [26], gliomas [27], thyroid gland neoplasms [28], and hematological neoplasms such as acute myeloid leukemia, acute lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, and myelodysplastic syndromes [29–32].

The role that this pathway and its components play in hematopoietic system and hematological neoplasm pathogenesis and progression remains controversial [33]. For instance, the enforced expression of a constitutively active YAP mutant does not affect the normal hematopoietic stem cell biology [34]. In contrast, MST1 gene inactivation causes primary immunodeficiency characterized by susceptibility to chronic infection and frequent autoimmune manifestations [35, 36].

The low LATS2 gene expression in adult T cell leukemia/lymphoma and natural killer leukemia cells results in decreased pro-apoptotic gene expression in leukemic cells and the consequent resistance to chemotherapy [37]. On the other hand, high LATS2 gene expression accounts for leukemogenesis in acute myeloid leukemia [32, 38].

In our study, the expression of the Hippo pathway-related genes SAV1 and TAZ, and the pro-apoptotic gene BAD was downregulated in PMF patients when compared with the control. PV and ET patients also presented low expression of various Hippo pathway-related genes, including MST2, SAV1, and TAZ. The low expression of these genes was associated with deregulated expression of apoptosis-related genes, upregulated expression of the anti-apoptotic genes BCL-2 and BCL-XL, and downregulated expression of BAK and BAD genes. Altogether, these data suggested that deregulation of both signaling pathways is involved in the exacerbated cell proliferation and cell death resistance in MPN.

Another relevant finding was the association between driver mutations and Hippo pathway gene expression, especially in PMF patients; those patients who harbored JAK2V617F mutation presented low expression of MST1, MOBIA, and MOBIB. The heterozygous MST1/MST2 kinase inactivation leads to accelerated development of lethal myelofibrosis, associated to innate immune proinflammatory cytokine production, including IL-1β and IL-6, in a JAK2V617F model [39].

Our data also suggested the existence of association among Hippo pathway genes, apoptosis-related genes, hematological data, and clinical data. In the three disease subtypes studied herein, MST1 correlated with platelet counts, WBC counts, or thrombotic events. MST1 is an Mpl ligand-inducible serine/threonine kinase that induces signaling cascades and functions to potentiate polyploidization and differentiation during megakaryopoiesis [40]. Hence, the low MST1 expression in these MPN seemed to be an attempt to counterbalance megakaryocyte proliferation, which is common in these neoplasms.

The expression of c-myb, HOXA9, LYN, cystatin c, and LTC4s differs between bone marrow and peripheral blood samples from patients with acute myeloid leukemia [41]. The gene expression analysis of total mRNA of all matched pairs of a group of patients with chronic lymphocytic leukemia, using Affymetrix U133A 2.0 arrays, has identified 543 genes with at least 1.5-fold higher expression in bone marrow than in peripheral blood, and 192 genes with at least 1.5-fold higher expression in peripheral blood than in bone marrow [42]. These reports are in line with the findings reported here that the expression of Hippo pathway genes differed between bone marrow and peripheral blood, and that the main changes occurred in peripheral blood.

In recent years, LATS kinases have attracted the interest of many researchers due to their broad range of biological activities in cell cycle regulation, differentiation, and motility, as well as the diverse pathological outcomes of their deregulation [43]. As the LATS2 gene expression was decreased in PV patients, we examined its role in cells with
malignant phenotype, resistance to death, and exacerbated proliferation through the induction of ectopic expression of \textit{LATS2} gene in HEL.92.1.7 cells. The \textit{LATS2} gene overexpression increased the apoptosis rate and decreased cell proliferation rate in HEL.92.1.7 cells.

Ectopic expression of human \textit{LATS2} induces apoptosis in two lung cancer cell lines, A549 and H1299 [44]. The anti-apoptotic proteins BCL-2 and BCL-X\textsubscript{L}, but not the pro-apoptotic protein BAX, are downregulated in transduced human lung cancer cells, as demonstrated by Western blotting [44]. Overexpression of either BCL-2 or BCL-X\textsubscript{L} genes in these cells suppresses the LATS2-mediated caspase cleavage and apoptosis, confirming that \textit{LATS2} gene induces human lung cancer cell apoptosis through down-regulation of the anti-apoptotic proteins BCL-2 and BCL-X\textsubscript{L} [44]. Overexpression of \textit{LATS2} gene in human glioblastoma cells U-372 MG is associated with inhibition of cell proliferation, migration, and invasion, as well as with increased levels of phosphorylated TAZ and YAP proteins [45]. \textit{LATS2} is a potential tumor suppressor gene in human glioblastoma cells, and its downregulation may contribute to the pathogenesis of this disease [45]. In this context, our data indicate that \textit{LATS2} also acts as tumor suppressor in MPN.

We also analyzed the potential association between Hippo pathway-related genes and the patients’ mutation status. The CALR mutation was associated with increased \textit{MOB1B} and \textit{SAV1} gene expression in ET patients, while the JAK2V617F mutation was associated with decreased \textit{MST1}, \textit{MOB1A}, and \textit{MOB1B} expression in PMF patients, suggesting that the JAK2V617F mutation favored Hippo pathway deregulation.

In \textit{Drosophila} sp., the integrated action of the JAK/STAT pathway and Hippo signaling pathways controls development by independently regulating the transcription of common target genes, such as \textit{CycE} and \textit{E2f1} to control cell proliferation, and \textit{Diap1} to control cell survival [46].

The heterozygous Hippo kinase \textit{MST1} inactivation significantly accelerates myelofibrotic transformation into JAK2V617F MPN through its action on innate immune signaling and proinflammatory cytokine production [39]. No association between components of the Hippo pathway and the CALR mutation has been described so far.

Taken the results altogether, we concluded that expression of Hippo pathway-related genes is deregulated and \textit{LATS2} is a tumor suppressor gene in MPN patients. The altered expression of Hippo pathway-related genes seems to mediate the exacerbated cell proliferation and apoptosis impairment in MPN patients.

\textbf{Supplementary Information} The online version contains supplementary material available at \url{https://doi.org/10.1007/s12032-022-01696-x}.

\textbf{Author contributions} All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by MdCC, JGC, LMP, MGB-C, GMB, LB, TM, RT, NdSN, and EXS. The first draft of the manuscript was written by MdCC and FAdC. The manuscript was reviewed by LdF-P, APY, and FAdC. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

\textbf{Funding} This study was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES; Finance Code 001); the São Paulo Research Foundation (FAPESP; Regular Research Grant #2018/19714-7; CTC Grant #2013/08135-2; INCTC Grant #2014/50947-7; Young Investigator Grant# 2015/21866-1), and by the National Council for Scientific and Technological Development (CNPq Grants #163064/2018-0, #169093/2018-2, and #305959/2018-2). MCC and MGBC are recipients from FAPESP scholarships (Grants #2014/04234-9 and #2015/23555-3, respectively).

\textbf{Declarations} Conflicts of interest The authors have no relevant financial or non-financial interests to disclose.

\textbf{References}

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.
2. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737–40.
3. C. Diaconu C, Gurban P, Mambet C, Chivu-Economescu M, G. Necula L, Matei L, et al. Programmed Cell Death Deregulation in BCR-ABL1-Negative Myeloproliferative Neoplasms. In: Gali-Muhtasib H, Nasser Rahal O, editors. Programmed Cell Death. IntechOpen; 2020 [cited 2021 Mar 23]. Available from: \url{https://www.intechopen.com/books/programmed-cell-death/progr ammed-cell-death-deregulation-in-bcr-abl1-negative-myeloprolife rative-neoplasms}
4. Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, et al. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocytocemia and Myelofibrosis. J Hematol Oncol. 2012;5:2.
5. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJF, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.
7. Huijsmans CJI, Poord J, Savellkhow PML, Hermans MHA. Sensitive detection and quantification of the JAK2V617F allele by real-time PCR. J Mol Diagn. 2011;13:558–64.
8. Kodama T, Hikita H, Kawaguchi T, Shigeiaka M, Shinizumi S, Hayashi Y, et al. Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ. 2012;19:1856–69.
9. Pandaran AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.
22. Guo H, Hao R, Wei Y, Sun D, Sun S, Zhang Z. Optimization of
28. de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V,
27. Ji T, Liu D, Shao W, Yang W, Wu H, Bian X. Decreased expres-
26. Sasaki H, Kawano O, Endo K, Suzuki E, Yukiue H, Kobayashi
25. Kosaka Y, Mimori K, Tanaka F, Inoue H, Watanabe M, Mori M.
24. Badouel C, Garg A, McNeill H. Herding Hippos: regulating
19. Barbui T, Thiele J, Gisslinger H, Gisslinger H, Kvasnicka HM, Vannucchi AM,
18. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates
17. Hong W, Guan K-L. The YAP and TAZ transcription co-acti-
16. Couzens AL, Knight JDR, Kean MJ, Teo G, Weiss A, Dunham
13. Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R-I,
12. Araki M, Komatsu N. Novel molecular mechanism of cellular
11. Chaligné R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz
10. Plo I, Bellanné-Chantelot C, Mosca M, Mazzi S, Marty C, Vain-
9. Plo I, Bellanné-Chantelot C, Mosca M, Mazzi S, Marty C, Vain-
8. Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family pro-
7. Couzens AL, Knight JDR, Kean MJ, Teo G, Weiss A, Dunham WH, et al. Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci Signal. 2013;6:rs15.
6. Behrens J, van Loo P, Sebti SM, et al. RIPK1 is a key mediator of TNF receptor-induced apoptosis in vivo. Cancer Cell. 2008;14:453–64.
5. de Launoit X, Kneitz C, Wang X, et al. NF-kappaB-dependent apoptosis and proliferation in multiple myeloma cells. FEBS Lett. 2012;586:4311–8.
4. de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V, Franco R, et al. TAZ/WTTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer. 2011;47:926–33.
3. Dhyani A, Duarte ASS, Machado-Neto JA, Favaro P, Ortega MM, Olalla Saad ST. ANKH1D1 regulates cell cycle progression and proliferation in multiple myeloma cells. FEBS Lett. 2012;586:4311–8.
2. Badouel C, Garg A, McNeill H. Herding Hippos: regulating
1. Badouel C, Garg A, McNeill H. Herding Hippos: regulating